1
|
Ng B, Rowland HA, Wei T, Arunasalam K, Hayes EM, Koychev I, Hedegaard A, Ribe EM, Chan D, Chessell T, Ffytche D, Gunn RN, Kocagoncu E, Lawson J, Malhotra PA, Ridha BH, Rowe JB, Thomas AJ, Zamboni G, Buckley NJ, Cader ZM, Lovestone S, Wade-Martins R. Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability. Brain Commun 2022; 4:fcac267. [PMID: 36349119 PMCID: PMC9636855 DOI: 10.1093/braincomms/fcac267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 07/20/2022] [Accepted: 10/19/2022] [Indexed: 11/24/2022] Open
Abstract
Establishing preclinical models of Alzheimer's disease that predict clinical outcomes remains a critically important, yet to date not fully realized, goal. Models derived from human cells offer considerable advantages over non-human models, including the potential to reflect some of the inter-individual differences that are apparent in patients. Here we report an approach using induced pluripotent stem cell-derived cortical neurons from people with early symptomatic Alzheimer's disease where we sought a match between individual disease characteristics in the cells with analogous characteristics in the people from whom they were derived. We show that the response to amyloid-β burden in life, as measured by cognitive decline and brain activity levels, varies between individuals and this vulnerability rating correlates with the individual cellular vulnerability to extrinsic amyloid-β in vitro as measured by synapse loss and function. Our findings indicate that patient-induced pluripotent stem cell-derived cortical neurons not only present key aspects of Alzheimer's disease pathology but also reflect key aspects of the clinical phenotypes of the same patients. Cellular models that reflect an individual's in-life clinical vulnerability thus represent a tractable method of Alzheimer's disease modelling using clinical data in combination with cellular phenotypes.
Collapse
Affiliation(s)
- Bryan Ng
- Department of Physiology Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
- Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
| | - Helen A Rowland
- Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
- Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK
| | - Tina Wei
- Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
- Nuffield Department of Clinical Neurosciences, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
| | - Kanisa Arunasalam
- Nuffield Department of Clinical Neurosciences, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
| | - Emma Mee Hayes
- Nuffield Department of Clinical Neurosciences, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
| | - Ivan Koychev
- Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK
| | - Anne Hedegaard
- Present address: Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK
| | - Elena M Ribe
- Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK
| | - Dennis Chan
- Present address: Institute of Cognitive Neuroscience, University College London, London WC1N 3AZ, UK
| | - Tharani Chessell
- Neuroscience, Innovative Medicines and Early Development, AstraZeneca AKB, Granta Park, Cambridge, CB21 6GH, UK
| | - Dominic Ffytche
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, SE5 8AF, UK
| | - Roger N Gunn
- Invicro & Department of Brain Sciences, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
| | - Ece Kocagoncu
- Medical Research Council Cognition and Brain Sciences Unit, Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 7EF, UK
| | - Jennifer Lawson
- Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK
| | - Paresh A Malhotra
- Department of Brain Sciences, Imperial College London, Charing Cross Campus, London W6 8RP, UK
| | - Basil H Ridha
- Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
| | - James B Rowe
- Medical Research Council Cognition and Brain Sciences Unit, Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 7EF, UK
| | - Alan J Thomas
- Translational and Clinical Research Institute, Newcastle University, Newcastle, UK
| | - Giovanna Zamboni
- Present address: Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena Italy
| | - Noel J Buckley
- Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
- Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK
| | - Zameel M Cader
- Zameel M. Cader, Nuffield Department of Clinical Neurosciences Kavli Institute for Nanoscience Discovery Dorothy Crowfoot Hodgkin Building University of Oxford, South Parks Road Oxford OX1 3QU, UK E-mail:
| | - Simon Lovestone
- Correspondence may also be addressed to: Simon Lovestone Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK E-mail:
| | - Richard Wade-Martins
- Correspondence to: Richard Wade-Martins Department of Physiology, Anatomy and Genetics Kavli Institute for Nanoscience Discovery Dorothy Crowfoot Hodgkin Building University of Oxford, South Parks Road Oxford OX1 3QU, UK E-mail:
| |
Collapse
|
2
|
Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, Rowe JB, Thomas AJ, Rochester L, Chan D, Tom B, Malhotra P, Ballard C, Chessell I, Ritchie CW, Raymont V, Leroi I, Lengyel I, Murray M, Thomas DL, Gallacher J, Lovestone S. Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. BMJ Open 2019; 9:e024498. [PMID: 30904851 PMCID: PMC6475176 DOI: 10.1136/bmjopen-2018-024498] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION Recent failures of potential novel therapeutics for Alzheimer's disease (AD) have prompted a drive towards clinical studies in prodromal or preclinical states. However, carrying out clinical trials in early disease stages is extremely challenging-a key reason being the unfeasibility of using classical outcome measures of dementia trials (eg, conversion to dementia) and the lack of validated surrogate measures so early in the disease process. The Deep and Frequent Phenotyping (DFP) study aims to resolve this issue by identifying a set of markers acting as indicators of disease progression in the prodromal phase of disease that could be used as indicative outcome measures in proof-of-concept trials. METHODS AND ANALYSIS The DFP study is a repeated measures observational study where participants will be recruited through existing parent cohorts, research interested lists/databases, advertisements and memory clinics. Repeated measures of both established (cognition, positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) markers of pathology, structural MRI markers of neurodegeneration) and experimental modalities (functional MRI, magnetoencephalography and/or electroencephalography, gait measurement, ophthalmological and continuous smartphone-based cognitive and other assessments together with experimental CSF, blood, tear and saliva biomarkers) will be performed. We will be recruiting male and female participants aged >60 years with prodromal AD, defined as absence of dementia but with evidence of cognitive impairment together with AD pathology as assessed using PET imaging or CSF biomarkers. Control participants without evidence of AD pathology will be included at a 1:4 ratio. ETHICS AND DISSEMINATION The study gained favourable ethical opinion from the South Central-Oxford B NHS Research Ethics Committee (REC reference 17/SC/0315; approved on 18 August 2017; amendment 13 February 2018). Data will be shared with the scientific community no more than 1 year following completion of study and data assembly.
Collapse
Affiliation(s)
- Ivan Koychev
- Department of Psychiatry, University of Oxford, Oxford, UK
| | | | - Tharani Chessell
- IMED Neuroscience, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK
| | - Clare Mackay
- Department of Psychiatry, University of Oxford, Oxford, UK
| | - Roger Gunn
- Invicro, London, UK
- Department of Medicine, Imperial College London, London, UK
| | - Barbara Sahakian
- Department of Psychiatry, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Alan J Thomas
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - Lynn Rochester
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - Dennis Chan
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- MRC Cognition and Brain Sciences Unit, Cambridge, Cambridgeshire, UK
| | - Brian Tom
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
| | - Paresh Malhotra
- Department of Neurology, Imperial College London Faculty of Medicine, London, UK
| | | | - Iain Chessell
- IMED Neuroscience, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK
| | - Craig W Ritchie
- Department of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Vanessa Raymont
- Department of Psychiatry, University of Oxford, Oxford, UK
- Department of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Iracema Leroi
- Manchester Academic Health Sciences Centre, Institute of Brain, Behaviour, and Mental Health, Manchester, UK
| | | | | | - David L Thomas
- Leonard Wolfson Experimental Neurology Centre, University College London Institute of Neurology, London, London, UK
| | - John Gallacher
- Department of Psychiatry, University of Oxford, Oxford, UK
| | | |
Collapse
|
3
|
Ostenfeld T, Pomfret M, Billinton A, Chessell I, Chessell T, Lindqvist E, Valencia ZS, Groves M, Narwal R, Tatipalli M, Lee N, Turner R, Tan K, Dudley A. [O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.193] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Thor Ostenfeld
- AstraZenecaCambridgeUnited Kingdom
- AstraZenecaGothenburgSweden
- MedimmuneGaithersburgMDUSA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|